Literature DB >> 24009229

Regulation of vascular leak and recovery from ischemic injury by general and VE-cadherin-restricted miRNA antagonists of miR-27.

Jennifer A Young1, Ka Ka Ting, Jia Li, Thorleif Moller, Louise Dunn, Ying Lu, Joshua Moses, Leonel Prado-Lourenço, Levon M Khachigian, Martin Ng, Philip A Gregory, Gregory J Goodall, Anna Tsykin, Ilana Lichtenstein, Christopher N Hahn, Nham Tran, Nicholas Shackel, James G Kench, Geoffrey McCaughan, Mathew A Vadas, Jennifer R Gamble.   

Abstract

Cellular junctions are essential to the normal functioning of the endothelium and control angiogenesis, tissue leak, and inflammation. From a screen of micro RNAs (miRNAs) altered in in vitro angiogenesis, we selected a subset predicted to target junctional molecules. MiR-27a was rapidly downregulated upon stimulation of in vitro angiogenesis, and its level of expression is reduced in neovessels in vivo. The downregulation of miR-27a was essential for angiogenesis because ectopic expression of miR-27a blocked capillary tube formation and angiogenesis. MiR-27a targets the junctional, endothelial-specific cadherin, VE-cadherin. Consistent with this, vascular permeability to vascular endothelial growth factor in mice is reduced by administration of a general miR-27 inhibitor. To determine that VE-cadherin was the dominant target of miR-27a function, we used a novel technology with "Blockmirs," inhibitors that bind to the miR-27 binding site in VE-cadherin. The Blockmir CD5-2 demonstrated specificity for VE-cadherin and inhibited vascular leak in vitro and in vivo. Furthermore, CD5-2 reduced edema, increased capillary density, and potently enhanced recovery from ischemic limb injury in mice. The Blockmir technology offers a refinement in the use of miRNAs, especially for therapy. Further, targeting of endothelial junctional molecules by miRNAs has clinical potential, especially in diseases associated with vascular leak.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24009229     DOI: 10.1182/blood-2012-12-473017

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  25 in total

Review 1.  Protein Interactions at Endothelial Junctions and Signaling Mechanisms Regulating Endothelial Permeability.

Authors:  Yulia A Komarova; Kevin Kruse; Dolly Mehta; Asrar B Malik
Journal:  Circ Res       Date:  2017-01-06       Impact factor: 17.367

Review 2.  Endothelial permeability and VE-cadherin: a wacky comradeship.

Authors:  Julie Gavard
Journal:  Cell Adh Migr       Date:  2013-12-05       Impact factor: 3.405

3.  MicroRNAs and cancer: Key paradigms in molecular therapy.

Authors:  Weige Tan; Bodu Liu; Shaohua Qu; Gehao Liang; Wei Luo; Chang Gong
Journal:  Oncol Lett       Date:  2017-12-19       Impact factor: 2.967

Review 4.  MiRNA inhibition in tissue engineering and regenerative medicine.

Authors:  Kelsey R Beavers; Christopher E Nelson; Craig L Duvall
Journal:  Adv Drug Deliv Rev       Date:  2014-12-29       Impact factor: 15.470

5.  MicroRNA-150 Suppression of Angiopoetin-2 Generation and Signaling Is Crucial for Resolving Vascular Injury.

Authors:  Charu Rajput; Mohammad Tauseef; Mohammad Farazuddin; Pascal Yazbeck; Md-Ruhul Amin; Vijay Avin Br; Tiffany Sharma; Dolly Mehta
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-01-07       Impact factor: 8.311

6.  Therapeutic regulation of VE-cadherin with a novel oligonucleotide drug for diabetic eye complications using retinopathy mouse models.

Authors:  Ka Ka Ting; Yang Zhao; Weiyong Shen; Paul Coleman; Michelle Yam; Tailoi Chan-Ling; Jia Li; Thorleif Moller; Mark Gillies; Mathew A Vadas; Jennifer R Gamble
Journal:  Diabetologia       Date:  2018-11-15       Impact factor: 10.122

7.  A Stromal Cell-Derived Factor 1α Analogue Improves Endothelial Cell Function in Lipopolysaccharide-Induced Acute Respiratory Distress Syndrome.

Authors:  Changrun Guo; Andrew Goodwin; Joy N Jones Buie; James Cook; Perry Halushka; Kelley Argraves; Basilia Zingarelli; Xian Zhang; Liping Wang; Hongkuan Fan
Journal:  Mol Med       Date:  2016-03-18       Impact factor: 6.354

8.  miR-27a-3p protects against blood-brain barrier disruption and brain injury after intracerebral hemorrhage by targeting endothelial aquaporin-11.

Authors:  Tianyang Xi; Feng Jin; Ying Zhu; Jialu Wang; Ling Tang; Yanzhe Wang; David S Liebeskind; Fabien Scalzo; Zhiyi He
Journal:  J Biol Chem       Date:  2018-10-18       Impact factor: 5.157

Review 9.  Targeting microRNAs to Regulate the Integrity of the Blood-Brain Barrier.

Authors:  Juntao Wang; Fang Xu; Xiaoming Zhu; Xianghua Li; Yankun Li; Jia Li
Journal:  Front Bioeng Biotechnol       Date:  2021-06-11

Review 10.  Development of Novel Therapeutics Targeting the Blood-Brain Barrier: From Barrier to Carrier.

Authors:  Jia Li; Meng Zheng; Olga Shimoni; William A Banks; Ashley I Bush; Jennifer R Gamble; Bingyang Shi
Journal:  Adv Sci (Weinh)       Date:  2021-06-03       Impact factor: 16.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.